Should we quantify insulin resistance in patients with renal disease?
Cardiovascular disease is a major cause of morbidity and mortality in dialysis patients. Vascular disease develops before the initiation of dialysis, and it is now recognized that chronic kidney disease (CKD) is an independent risk factor for cardiovascular disease. Death from cardiovascular disease is a more common endpoint of CKD than progression to dialysis. There are multiple mechanisms that contribute to the increased vascular risk of CKD, one of which is the presence of insulin resistance (IR). CKD is characterised by many features of the metabolic syndrome, and features of IR are also observed in dialysis and transplant patients. IR may be quantified by several different methods. One such method is homeostatic model assessment (HOMA) technique, which derives a measurement of IR from fasting plasma glucose and insulin concentrations. The HOMA index has been demonstrated to be an independent predictor of survival in dialysis patients. CKD is characterised by a chronic inflammatory response and abnormalities in the production and regulation of adipose tissue derived proteins, which may contribute to the development of IR. There are a range of interventions including diet and exercise programmes or medications that may influence IR; however, the impact of these interventions in the context of CKD has not been systematically evaluated.
Shen
Yvonne
Y
Department of Nephrology, Prince of Wales Hospital, Randwick, Australia.
Peake
Philip W
PW
Kelly
John J
JJ
D002318:Cardiovascular Diseases / Q000209:etiology; D016207:Cytokines / Q000378:metabolism; D006706:Homeostasis; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D007333:Insulin Resistance; D007674:Kidney Diseases / Q000150:complications / Q000378:metabolism*; D024821:Metabolic Syndrome / Q000175:diagnosis*; D012307:Risk Factors
D016207:Cytokines; D018836:Inflammation Mediators